Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi Interventional Approaches to Mitigate HIV Reservoirs
NCT06805656Phase 2Recruiting
- Sponsor
- Federal University of São Paulo
- Start
- Jul 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
A Phase 2 trial of maraviroc, dolutegravir, WT1/hTERT/Survivin-loaded dendritic cell vaccine, auranofin, nicotinamide in human immunodeficiency virus infection (HIV), sponsored by Federal University of São Paulo. Started Jul 2026; status: recruiting.
02
Drugs
maravirocdolutegravirWT1/hTERT/Survivin-loaded dendritic cell vaccineauranofinnicotinamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06805656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06805656.